Can-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
The Phase IIa clinical trial is open-label study evaluating Namodenoson in patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one prior line of therapy. The study is assessing the safety, clinical activity, and pharmacokinetics (PK) of Namodenoson, administered orally at a dose of 25 mg twice daily in continuous 28-day cycles. Approximately 20 evaluable patients are expected to be enrolled.
The trial is led by Prof. Salomon Stemmer, a prominent Oncologist and Key Opinion Leader at the Davidoff Center, Rabin Medical Center, Israel. Namodenoson has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer.
'We are pleased to report that 50% of the planned patient cohort has already been enrolled and that Namodenoson has demonstrated a favourable safety profile,' stated Prof. Salomon Stemmer. 'There is a critical unmet need for safe and effective treatment options for patients with advanced pancreatic cancer who have exhausted standard therapies. This study gives us the opportunity to advance a novel therapeutic approach for this challenging disease, stated Dr. Sari Fishman, VP of Business Development at Can-Fite.'
Can-Fite looks forward to engaging with potential partners and collaborators at BIO 2025 as it continues to progress its clinical pipeline.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are 'forward looking statements'. Forward-looking statements can be identified by the use of forward-looking words such as 'believe,' 'expect,' 'intend,' 'plan,' 'may,' 'should' or 'anticipate' or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offerings, the satisfaction of customary closing conditions related to the offerings and the intended use of proceeds therefrom. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the 'Risk Factors' section of Can-Fite's Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contact
Can-Fite BioPharma
Motti Farbstein
[email protected]
+972-3-9241114
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Journals
a day ago
- Business Journals
HCA Midwest Health first in region to offer new, non-surgical liver tumor treatment
Each year, it is estimated more than 40,000 people will be diagnosed with liver cancer – and those numbers are increasing. Treatments for liver cancer can be complex and commonly include surgery that can result in a long recovery process, pain and countless side effects. That is, until now. HCA Midwest Health's Menorah Medical Center is the first hospital in a four-state region to offer histotripsy, a new, non-invasive treatment for cancerous liver tumors. Approved by the U.S. Food and Drug Administration in 2023, this innovative therapy uses high-frequency ultrasound waves to destroy liver tumors without the need for incisions or probes, often resulting in shorter recovery time and less harm to the patient's liver and surrounding areas. 'Liver cancer patients often undergo extensive and painful surgery. Or worse, they are told there is no hope for further treatment,' said Dr. Joe Cates, a board-certified vascular and general surgeon with Kansas City Vascular and General Surgery. 'Now, we can offer a permanent solution with a minor procedure.' expand Histotripsy can pinpoint high-frequency ultrasound to an energy wave that liquefies tissue. In this procedure, it is targeted and precise to the millimeter and liquefies cancer tumors. Using computed tomography and ultrasound guidance, hyper-focused sound waves are delivered through the body to the liver lesion, where they destroy the tumor while sparing normal tissue. The technology allows physicians to treat liver cancer without surgery, pain, incisions or radiation. 'With this type of treatment, we are able to preserve the healthy area of the liver around the tumor,' Dr. Cates said. The benefits of the minimally invasive, same-day procedure include less pain and no bleeding, providing the opportunity for patients to get back to daily activities sooner. The procedure itself can take between 10 minutes and three hours, with the active treatment portion ranging from five to 30 minutes per tumor. The total time can vary based on factors like tumor size and location, and the number of tumors being treated. 'This new procedure is important because liver cancers are becoming more common. This breakthrough treatment can change and improve the lives of so many patients in the region,' Dr. Cates said. For more information about histotripsy – or for any questions about cancer – call the HCA Healthcare Sarah Cannon Network askSARAH helpline at (816) 448-7737. More information is also available at expand A home for new and innovative treatments to advance patient care Cancer care is an ever-changing field, with new treatments and technologies always evolving to improve patient outcomes. Menorah Medical Center has a rich history of quality cancer care and being a leader in offering the latest technologies, innovations and treatments, including: Robotic Surgery: Menorah was an early-adopter and remains a leader in robotic-assisted surgical systems. Surgeons treat highly complex cancers including colorectal, breast, lung and other types of cancer with many leading-edge robotic systems. The hospital has also been named a robotic center of excellence and has served as a teaching site for surgeons across the United States and from other countries. True Beam: A minimally invasive form of stereotactic radiosurgery that uses precisely focused beams of radiation to treat brain disorders and tumors without traditional surgery, this precision targeting delivers a high dose of radiation to a specific area of the brain while minimizing damage to surrounding healthy tissue. Mammosite for Breast Cancer: Menorah Medical Center is the only hospital in Johnson County to offer this advanced breast cancer treatment. 'The region continues to grow, and we need to grow our hospital services to ensure we're continuing to meet the community's needs,' said Sean Kamber, Menorah Medical Center CEO. 'That means not only investing in the latest equipment, providing cutting-edge treatments and expanding and upgrading our state-of-the-art technology. It also means continuing to recruit the best physicians, nurses and specialized support staff to provide high-quality, compassionate healthcare.' One of Kansas City's premier healthcare providers, HCA Midwest Health is comprised of seven hospitals and dozens of physician practices, surgery centers and more, including Research Medical Center, Overland Park Regional Medical Center, Centerpoint Medical Center, Menorah Medical Center, Lee's Summit Medical Center, Belton Regional Medical Center and Lafeyette Regional Health Center. Visit for more.
The Onion
2 days ago
- The Onion
FDA Recalls 3 Oranges To Prove They Can Juggle
SILVER SPRING, MD—Issuing a public warning for Americans to watch or they might miss out, the U.S. Food and Drug Administration reportedly recalled three navel oranges Wednesday to prove that they could juggle. 'Toss 'em here,' said spokesperson John Lavietes, adding that American consumers who had recently purchased navel, Valencia, or blood oranges should not consume the citrus fruits but instead bring three of them to the nearest FDA office so the federal agency could show them something. 'It's been a while, but we can definitely do it. Organic, GMO, even a mandarin or tangelo should be brought to this lectern immediately. Come on, any region or distributor works. They have to be firm, though. If they're not firm, we can't do it.' At press time, the FDA had recalled one more orange to replace the one that had rolled under the table.
Yahoo
3 days ago
- Yahoo
Ohio-made chocolate recalled
(WJW) — Chocolate made in northeast Ohio is being recalled because it may contain an undeclared milk allergen, which the U.S. Food and Drug Administration warns could cause a serious or life-threatening reaction to people who have an allergy or severe sensitivity to milk. According to the FDA, the recall applies to Wegmans Semi – Sweet Chocolate Nonpareils produced by Mellace Family Brands California, Inc. of Warren, Ohio. Homemade fireworks exploded in local mobile home The recalled product was distributed through Wegmans retail stores in Delaware, Maryland, Massachusetts, North Carolina, New Jersey, New York, Pennsylvania, Virginia, and Washington D.C., according to the FDA. Lunch meat recalled nationwide: What to know Here's what to check for: The product is packaged in a plastic tub labeled Wegmans Semi-Sweet Chocolate Nonpareils 18.5oz (1LB 2.5OZ) 524g, UPC 0 77890 49787 6, SCC 10077890497873. Best By and Lot code are located on the left side of the tub. The affected lot codes are: 55021 BEST BY: DEC 28, 2025 55031 BEST BY: DEC 29, 2025 55491 BEST BY: FEB 13, 2026 55501 BEST BY: FEB 14, 2026 56061 BEST BY: APR 11, 2026 56071 BEST BY: APR 12, 2026 So far, no illnesses have been reported. CLICK HERE to learn more about this recalled product and how to return the item for a refund. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
